company logo
Latest News

Apr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers

Phase 2a RSV Challenge Study Planned for Q3 2017

London, UK, 24th April 2017 / ReViral, a UK based biotechnology company focused on the discovery and development...

Mar 9, 2017
Ian Dukes joins the ReViral Board
London, UK, 9th March 2017 - ReViral are proud to announce that Ian Dukes has joined the ReViral Board.

ReViral Ltd, a company, focused on the discovery and development of breakthrough products...

Oct 31, 2016
ReViral initiates Phase 1 clinical trial of potent oral inhibitor against Respiratory Syncytial Virus

London, UK, 31st October 2016 - ReViral, an antiviral drug discovery and development company developing innovative therapies against Respiratory Syncytial Virus (RSV), announced today...

Oct 3, 2016
ReViral Announces Appointment of New Chief Executive Officer

London, UK, 3rd October 2016 / ReViral Ltd, a biotechnology company, aiming to help
patients infected with respiratory syncytial virus (RSV) by developing novel
compounds, is pleased to...

Jun 17, 2016
New laboratory facilities for ReViral

Refurbishment work is now completed at the North East Technology Park (NETPark) in Sedgefield and the laboratories have been formally handed over to ReViral. Chemistry work has commenced and virology screening will...

Jun 17, 2016
ReViral Relocates

ReViral is moving its London headquarters to laboratory and office space in the Stevenage Biocatalyst Bioincubator building.  This move into state of the art laboratory and office space will allow ReViral to...

Mar 30, 2016
ReViral Scientific Advisory Board meeting

30th March, 2016, London

ReViral held its first Scientific Advisory Board meeting in London in March and was chaired by Fred Hayden (Prof Emeritus, University of Virginia). Attending were...

Jan 1, 2016
Dr Elaine Thomas joins the ReViral team as Head of Virology

Dr Thomas is an experienced virologist with a wide range of virology R&D experience. She joined ReViral from hVivo where she has involved in a variety of pre-clinical and clinical virology studies. Elaine has...

Go to Archived News